Drug Topics
APRIL 5, 2025
Technological evolution promises to enhance patient care, reduce errors, and provide intelligent support that augments human expertise rather than replacing it.
Pharmacy Times
APRIL 5, 2025
Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 5, 2025
Medicare’s financial future unexpectedly got a lot rosier, at least according to some federal budget wonks. The Congressional Budget Office recently published its long-term predictions of the federal budget and buried a big surprise for people who follow the Medicare program. The government’s primary piggy bank that pays for Medicare benefits won’t be depleted until 2052 — 17 years later than what CBO analysts predicted last year.
Pharmacy Times
APRIL 5, 2025
Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate changes impacts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
APRIL 5, 2025
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
The Guardian - Pharmaceutical Industry
APRIL 5, 2025
Pharma firms are developing drugs that avoid the brains opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced In January, the US Food and Drug Administration (FDA) approved the first new type of painkiller in more than two decades. The decision roused excitement across the healthcare sector for a key reason: the drug, which is called suzetrigine and sold under the brand name Journavx, is not an opioid.
Expert insights. Personalized for you.
346 
Let's personalize your content